Overview
Silver nitrate is an inorganic compound with the chemical formula AgNO3. In its solid form, silver nitrate is coordinated in a trigonal planar arrangement. It is often used as a precursor to other silver-containing compounds. It is used in making photographic films, and in laboratory setting as a staining agent in protein visualization in PAGE gels and in scanning electron microscopy.
Indication
1%~2%溶液用于新生儿淋菌性眼炎的预防;0.5%~1%溶液用于结膜炎、沙眼急性期;0.3%溶液制成敷料用于Ⅱ度和清创后的Ⅲ度大面积烧伤,以预防铜绿假单胞菌、变形杆菌和其他革兰阴性菌的感染;10%~20%溶液或硝酸银棒局部使用,用于腐蚀生长过剩肉芽组织及疣。
Associated Conditions
No associated conditions information available.
Research Report
Comprehensive Monograph: Silver Nitrate (AgNO₃)
1.0 Executive Summary
Silver nitrate () is an inorganic compound with a long and multifaceted history in medicine, valued primarily as a topical anti-infective and chemical cauterizing agent.[1] Its therapeutic utility is derived from the potent, dual-action biological activity of the free silver ion (
), which is released upon dissolution in an aqueous environment.[2] This monograph provides a comprehensive analysis of its chemical properties, pharmacology, clinical applications, toxicology, and regulatory status.
The compound's mechanism of action is twofold. It exerts a broad-spectrum antimicrobial effect against gram-positive and gram-negative bacteria, fungi, and some viruses through multiple pathways, including the disruption of microbial proteins via binding to sulfhydryl groups, the destabilization of cell membranes, and the inhibition of DNA replication.[3] Concurrently, its caustic action on mammalian tissue results from the coagulation of cellular proteins to form a protective eschar. This process facilitates chemical debridement and provides effective hemostasis for minor capillary bleeding.[3]
Primary clinical applications are focused on topical treatments where both antimicrobial and caustic effects are desired. These include the cauterization of wounds, management of hypergranulation tissue, treatment of ulcers, control of epistaxis, and the removal of verrucae (warts) and skin tags.[7]
Clinical Trials
Title | Posted | Study ID | Phase | Status | Sponsor |
|---|---|---|---|---|---|
2025/02/20 | Not Applicable | Completed | Youssef Zaki | ||
2024/11/08 | Phase 2 | Not yet recruiting | Francesco Egro | ||
2024/10/08 | Not Applicable | Recruiting | |||
2024/04/12 | Phase 2 | Completed | Children Hospital and Institute of Child Health, Lahore | ||
2020/09/23 | Phase 4 | Completed | Umraniye Education and Research Hospital | ||
2018/12/20 | Phase 1 | UNKNOWN | |||
2015/11/13 | Early Phase 1 | Completed | Arwa Owais | ||
2015/08/11 | Phase 3 | Terminated | |||
2015/03/25 | Phase 4 | UNKNOWN | |||
2014/04/17 | Phase 4 | Completed |
FDA Drug Approvals
Approved Product | Manufacturer | NDC Code | Route | Strength | Effective Date |
|---|---|---|---|---|---|
| Boiron | 0220-0457 | ORAL | 6 [hp_C] in 6 [hp_C] | 9/23/2025 | |
| Boiron | 0220-0470 | ORAL | 10 [hp_M] in 10 [hp_M] | 9/23/2025 | |
| Boiron | 0220-0484 | ORAL | 6 [hp_X] in 1 1 | 9/23/2025 | |
| Newton Laboratories, Inc. | 55714-2471 | ORAL | 15 [hp_X] in 1 mL | 9/18/2025 | |
| Newton Laboratories, Inc. | 55714-4748 | ORAL | 15 [hp_X] in 1 mL | 8/20/2025 | |
| Natural Immunogenics Corp.dba SOVEREIGN NATURALS | 52166-053 | ORAL | 10 [hp_X] in 1 mL | 5/22/2025 | |
| Boiron | 0220-0461 | ORAL | 12 [hp_C] in 12 [hp_C] | 9/23/2025 | |
| Bray Group Limited | 65875-101 | TOPICAL | 30 mg in 40 mg | 7/18/2018 | |
| Teva Pharmaceuticals USA, Inc. | 0093-9614 | TOPICAL | 0.005 g in 1 mL | 11/6/2018 | |
| McKesson Medical-Surgical | 68599-6302 | TOPICAL | 25 mg in 1 g | 1/15/2021 |
EMA Drug Approvals
Approved Product | Authorization Holder | Status | Issued Date |
|---|---|---|---|
| No EMA approvals found for this drug. | |||
HSA Drug Approvals
Approved Product | Manufacturer | Approval Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No HSA approvals found for this drug. | |||||
NMPA Drug Approvals
Approved Product | Company | Approval Number | Drug Type | Dosage Form | Approval Date |
|---|---|---|---|---|---|
| No NMPA approvals found for this drug. | |||||
PPB Drug Approvals
Approved Product | Registration No. | Company | Licence No. | Strength | Registration Date |
|---|---|---|---|---|---|
| No PPB approvals found for this drug. | |||||
TGA Drug Approvals
Approved Product | ARTG ID | Sponsor | Registration Type | Status | Registration Date |
|---|---|---|---|---|---|
| Euphorbium compositum Nasal Spray | 94405 | Medicine | A | 5/20/2003 | |
| Avoca Caustic Applicator 75% w/w Cutaneous Stick silver nitrate bag | 278284 | Sutherland Medical Pty Limited | Medicine | A | 7/26/2016 |
| SILVER NITRATE APPLICATORS | 33738 | Medicine | A | 12/12/1991 | |
| Mucosa compositum N | 124349 | Medicine | A | 12/19/2005 | |
| Allergy Oral Spray | 351127 | Medicine | A | 12/8/2020 |
Health Canada Drug Approvals
Approved Product | Company | DIN | Dosage Form | Strength | Market Date |
|---|---|---|---|---|---|
| SILVER NITRATE LIQUID (S#106)-LIQ | total health centre | 02193434 | Liquid - Oral | 6 X / ML | 6/1/1997 |
| ARGENTUM NITRICUM D6 (10 20 30) - LIQ | weleda ag heilmittelbetriebe | 02121212 | Liquid - Oral | 6 D / ML | 12/31/1995 |
| HOMEO-FORM ST-LIQ | homeocan inc. | 02140667 | Liquid - Oral | 9 X / ML | 12/31/1995 |
| HEEL 135 TAB | 01969234 | Tablet - Oral | 6 D / TAB | 12/31/1992 | |
| ACIDUM PHOSPHORICUM PLEX | seroyal international inc. | 02233076 | Pellet
,
Tablet
,
Drops
,
Syrup
,
Granules
,
Liquid - Oral | 6 X | 4/6/1998 |
| ARGENTUM NITRICUM D6 LIQ | dr reckeweg canada | 02038625 | Liquid - Oral | 6 D / ML | 12/31/1993 |
| PHOSPHOR-HOMACCORD | 02229471 | Drops - Oral | 10 D / 100 ML | 7/24/1997 | |
| HOMEODEX 02 | distributions biodentcom inc. | 02232208 | Granules - Oral | 15 CH | 6/3/1998 |
| HOMEO-FORM MI-TAB | homeocan inc. | 02149362 | Tablet - Oral | 9 X | 12/31/1995 |
| MEDIPLEX 640 - LIQ | mediherb inc. | 02116901 | Liquid - Oral | 10 X / ML | 12/19/1996 |
CIMA AEMPS Drug Approvals
Approved Product | Company | Registration Number | Pharmaceutical Form | Prescription Type | Status |
|---|---|---|---|---|---|
| No CIMA AEMPS (Spain) approvals found for this drug. | |||||
Philippines FDA Drug Approvals
Approved Product | Company | License Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No Philippines FDA approvals found for this drug. | |||||
Saudi SFDA Drug Approvals
Approved Product | Company | License Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No Saudi SFDA approvals found for this drug. | |||||
Malaysia NPRA Drug Approvals
Approved Product | Company | Registration Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No Malaysia NPRA approvals found for this drug. | |||||
UK EMC Drug Information
Medicine Name | MA Holder | MA Number | Pharmaceutical Form | Active Ingredient | Authorization Date |
|---|---|---|---|---|---|
| No UK EMC drug information found for this drug. | |||||
Help Us Improve
Your feedback helps us provide better drug information and insights.
